CHIMERA BIO

Optimizing Drug Combinations of Existing Compounds

OUR TECHNOLOGY

FACT 1

Complex conditions can not be treated successfully with one compound

FACT 2

Well designed drug combinations may drastically reduce resistance induction and improve tolerability and specificity

FACT 3

Most interventions bases on compound combination were found by “trial and error” approach

More about our technology

Based of over 6 years of research conducted at Uniqe, Geneva and Switzerland.

Dose-response curve for each compound to identify low dose

Testing drug combinations and data modeling

Elimination of antagonistic molecules

CHIMERA BIO TECHNOLOGY

Our Team

Maarten Mennes

Chief Executieve Officer

Patrycja Nowak-Sliwinska

Chief Scientific Officer

Yves Kummer

Chief Commercial Officer

Proof of Concept

Combination therapy for Renal cancer. Synergistic drug combination containing CI-994, tabacin, erlotinib and desatinib. Patent filed September 24th 2019, UNIGE licenced by Chimera Bio B.V. in 2022. A total of 10 compounds were included in the study.

VIEW ALL ARTICLES